This summer 2022, Chemotargets was presenting CLARITYpv at several international audience conferences:
Read More
A formal collaboration to advance a common internal pipeline of drug development projects Barcelona, 16 March 2022 – Today we announce the start of the formal collaboration between Acellera…
CloudScientific as the local distributor in China of Chemotargets’ CLARITY and CLARITY PV technology platforms Shanghai, China and Barcelona, Spain – January 17th, 2022. Chemotargets is proud to appoint CloudScientific as the local…
Drug discovery biotech firm Chemotargets and the Centre for Genomic Regulation (CRG) have signed a strategic agreement to accelerate the development of new targeted therapies that respond to unmet clinical...
Read More
This week Chemotargets announces the launch of CLARITY PV, a new product for translational safety and pharmacovigilance professionals. Barcelona, July 5th, 2021. Chemotargets launches CLARITY PV, a new web-based platform…
The Innovative SME Seal, valid for three years, recognizes the high level of innovation in the projects, products and services of Chemotargets. Barcelona, June 1st, 2021. Chemotargets has been awarded…
In less than 12 months, the collaboration between Chemotargets and Galyan Bio yields a scaffold for first-in-class clinical candidates in difficult area of neurodegenerative disease. Chemotargets employed its proprietary AI-driven…
This public-private partnership will establish a framework for collaboration that promotes the creation of synergies between both institutions. Chemotargets has entered into a strategic alliance with the IMIM Hospital del…
The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest….
GENESIS Biomed and CREA Inversión will advise in the funding, which will allow the company to expand its activity in the discovery of new drugs. Barcelona, 14 April 2020 –…
